CTLA-4 expressed on T cells blunts the immune system's response to tumor antigens by blocking binding of B7 on antigen-presenting cells (APC) to CD28 on T cells, resulting in suppression of APC function and impaired activation of CD8+ T cells (19). The gene discussed is CTLA4; the disease is neoplasm.